The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Can the combination of HDAC inhibitor panobinostat plus tacrolimus and sirolimus reduce aGVHD?

Sep 7, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Lia Perez, Moffitt Cancer Center, Tampa, US. We asked, Can the combination of HDAC inhibitor panobinostat plus tacrolimus and sirolimus reduce aGVHD?

Can the combination of HDAC inhibitor panobinostat plus tacrolimus and sirolimus reduce aGVHD?

Lia Perez discusses findings of a preliminary study in which panobinostat, a histone deacetylase (HDAC) inhibitor, was tested for the ability to prevent GvHD. The maximum tolerated dose was established by the team and positive results were obtained in terms of GvHD response. Following on from these data, the group investigated a combination of panobinostat with tacrolimus and sirolimus for reducing rates of acute (a)GvHD.